159 related articles for article (PubMed ID: 37919427)
1. Spatial metabolomics identifies distinct tumor-specific and stroma-specific subtypes in patients with lung squamous cell carcinoma.
Wang J; Sun N; Kunzke T; Shen J; Zens P; Prade VM; Feuchtinger A; Berezowska S; Walch A
NPJ Precis Oncol; 2023 Nov; 7(1):114. PubMed ID: 37919427
[TBL] [Abstract][Full Text] [Related]
2. Spatial Metabolomics Identifies Distinct Tumor-Specific Subtypes in Gastric Cancer Patients.
Wang J; Kunzke T; Prade VM; Shen J; Buck A; Feuchtinger A; Haffner I; Luber B; Liu DHW; Langer R; Lordick F; Sun N; Walch A
Clin Cancer Res; 2022 Jul; 28(13):2865-2877. PubMed ID: 35395077
[TBL] [Abstract][Full Text] [Related]
3. Prediction of immune subtypes and overall survival in lung squamous cell carcinoma.
Su X; Gao H; Qi Z; Xu T; Wang G; Luo H; Cheng P
Curr Med Res Opin; 2023 Feb; 39(2):289-298. PubMed ID: 36245361
[TBL] [Abstract][Full Text] [Related]
4. Specific Lung Squamous Cell Carcinoma Prognosis-Subtype Distinctions Based on DNA Methylation Patterns.
Huang G; Zhang J; Gong L; Liu D; Wang X; Chen Y; Guo S
Med Sci Monit; 2021 Mar; 27():e929524. PubMed ID: 33661858
[TBL] [Abstract][Full Text] [Related]
5. The critical role of serum thymidine kinase 1(STK1) in predicting prognosis for immunotherapy in T4 stage lung squamous cell carcinoma.
Pan J; Liu H; Li S; Wei W; Mai J; Bian Y; Ning S; Li J; Zhang L
Heliyon; 2023 Mar; 9(3):e14129. PubMed ID: 36938402
[TBL] [Abstract][Full Text] [Related]
6. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
Yang K; Wu Y
BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analyses of a CD8
Chen L; Weng Y; Cui X; Li Q; Peng M; Song Q
BMC Bioinformatics; 2023 Jun; 24(1):238. PubMed ID: 37280525
[TBL] [Abstract][Full Text] [Related]
8. Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.
Jiang T; Shi J; Dong Z; Hou L; Zhao C; Li X; Mao B; Zhu W; Guo X; Zhang H; He J; Chen X; Su C; Ren S; Wu C; Zhou C
J Hematol Oncol; 2019 Jul; 12(1):75. PubMed ID: 31299995
[TBL] [Abstract][Full Text] [Related]
9. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior.
Perez-Villamil B; Romera-Lopez A; Hernandez-Prieto S; Lopez-Campos G; Calles A; Lopez-Asenjo JA; Sanz-Ortega J; Fernandez-Perez C; Sastre J; Alfonso R; Caldes T; Martin-Sanchez F; Diaz-Rubio E
BMC Cancer; 2012 Jun; 12():260. PubMed ID: 22712570
[TBL] [Abstract][Full Text] [Related]
10. High-Resolution Profiling of Head and Neck Squamous Cells Carcinoma Identifies Specific Biomarkers and Expression Subtypes of Clinically Relevant Vulnerabilities.
Zhu Y; Peng B; Luo X; Sun W; Liu D; Li N; Qiu P; Long G
Curr Med Chem; 2023 Nov; ():. PubMed ID: 37936459
[TBL] [Abstract][Full Text] [Related]
11. DNA damage repair gene signature model for predicting prognosis and chemotherapy outcomes in lung squamous cell carcinoma.
Wang X; Huang Z; Li L; Wang G; Dong L; Li Q; Yuan J; Li Y
BMC Cancer; 2022 Aug; 22(1):866. PubMed ID: 35941578
[TBL] [Abstract][Full Text] [Related]
12. Characterization of stemness features and construction of a stemness subtype classifier to predict survival and treatment responses in lung squamous cell carcinoma.
Lai J; Lin X; Zheng H; Xie B; Fu D
BMC Cancer; 2023 Jun; 23(1):525. PubMed ID: 37291533
[TBL] [Abstract][Full Text] [Related]
13. Multi-omics analysis at epigenomics and transcriptomics levels reveals prognostic subtypes of lung squamous cell carcinoma.
Xu Y; She Y; Li Y; Li H; Jia Z; Jiang G; Liang L; Duan L
Biomed Pharmacother; 2020 May; 125():109859. PubMed ID: 32036209
[TBL] [Abstract][Full Text] [Related]
14. Spatial metabolomics for evaluating response to neoadjuvant therapy in non-small cell lung cancer patients.
Shen J; Sun N; Zens P; Kunzke T; Buck A; Prade VM; Wang J; Wang Q; Hu R; Feuchtinger A; Berezowska S; Walch A
Cancer Commun (Lond); 2022 Jun; 42(6):517-535. PubMed ID: 35593195
[TBL] [Abstract][Full Text] [Related]
15. Identification of prognostic immune subtypes of lung squamous cell carcinoma by unsupervised consistent clustering.
Wang Y; Hou L; Yang M; Fan J; Wang Y; Sun L
Medicine (Baltimore); 2023 Sep; 102(37):e35123. PubMed ID: 37713826
[TBL] [Abstract][Full Text] [Related]
16. Identification of tumour-infiltrating myeloid subsets associated with overall survival in lung squamous cell carcinoma.
Lu J; Duan Y; Liu P; He X; Yang Y; Zhang R; Weng L
J Pathol; 2023 Jan; 259(1):21-34. PubMed ID: 36178315
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic subtypes predict outcomes in colorectal cancer.
Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
[TBL] [Abstract][Full Text] [Related]
18. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
[TBL] [Abstract][Full Text] [Related]
19. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
[TBL] [Abstract][Full Text] [Related]
20. Prediction of risk and clinical outcome of cuproptosis in lung squamous carcinoma.
Zhang Y; Zhou J; Li H; Liu Y; Li J
BMC Pulm Med; 2023 Jun; 23(1):205. PubMed ID: 37308925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
